{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:17:27Z","timestamp":1769599047096,"version":"3.49.0"},"reference-count":0,"publisher":"OAE Publishing Inc.","content-domain":{"domain":["oaepublish.com"],"crossmark-restriction":false},"short-container-title":["CDR"],"DOI":"10.20517\/cdr.2021.27","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:47:15Z","timestamp":1624520835000},"update-policy":"https:\/\/doi.org\/10.20517\/oae.crossmark.policy","source":"Crossref","is-referenced-by-count":1,"title":["Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?"],"prefix":"10.20517","author":[{"given":"Kyung Bo","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8410","published-online":{"date-parts":[[2021]]},"container-title":["Cancer Drug Resistance"],"original-title":[],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T08:45:31Z","timestamp":1705567531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oaepublish.com\/articles\/cdr.2021.27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":0,"URL":"https:\/\/doi.org\/10.20517\/cdr.2021.27","relation":{},"subject":[],"published":{"date-parts":[[2021]]}}}